Clinical trial
Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer
NCT00075504 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00075504 |
|---|---|
| Title | Triapine and Gemcitabine Hydrochloride in Gallbladder Cancer |
| Official title | A Phase II Study of Triapine in Combination With Gemcitabine in Adenocarcinoma of the Biliary Ducts and Gall Bladder |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Stage II Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer |
| Intervention type | Drug |
| Interventions | triapine, gemcitabine |
| Enrollment | 33 |
| Start date | Nov 1, 2003 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Jan 12, 2004 |
| Last update posted | Sep 28, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: